Learning Objectives:

  1. Familiarize ourselves with the immune microenvironment in AML
  2. Appraise the major clinical studies evaluating immune checkpoint inhibitors (ICI) against the PD-1/PD-L1 axis, in the management of AML
  3. Identify key areas of unmet need in the study of immune checkpoint inhibitors in the management of AML
Session date: 
09/29/2022 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Athalia Pyzer, MD PhD